Development of an Automated Chemiluminescence Assay System for Quantitative Measurement of Multiple Anti-SARS-CoV-2 Antibodies.
COVID-19
SARS-CoV-2
automated chemiluminescent enzyme immunoassay
multiple antibody measurements
quantitative serological test
Journal
Frontiers in microbiology
ISSN: 1664-302X
Titre abrégé: Front Microbiol
Pays: Switzerland
ID NLM: 101548977
Informations de publication
Date de publication:
2020
2020
Historique:
received:
11
11
2020
accepted:
17
12
2020
entrez:
1
2
2021
pubmed:
2
2
2021
medline:
2
2
2021
Statut:
epublish
Résumé
Serological tests for COVID-19 have been instrumental in studying the epidemiology of the disease. However, the performance of the currently available tests is plagued by the problem of variability. We have developed a high-throughput serological test capable of simultaneously detecting total immunoglobulins (Ig) and immunoglobulin G (IgG) against nucleocapsid protein (NP) and spike protein (SP) and report its performance in detecting COVID-19 in clinical samples. We designed and prepared reagents for measuring NP-IgG, NP-Total Ig, SP-IgG, and SP-Total Ig (using N-terminally truncated NP (ΔN-NP) or receptor-binding domain (RBD) antigen) dedicated automated chemiluminescent enzyme immunoassay analyzer AIA-CL1200. After determining the basal thresholds based on 17 sera obtained from confirmed COVID-19 patients and 600 negative sera, the clinical validity of the assay was evaluated using independent 202 positive samples and 1,000 negative samples from healthy donors. All of the four test parameters showed 100% specificity individually (1,000/1,000; 95%CI, 99.63-100). The sensitivity of the assay increased proportionally to the elapsed time from symptoms onset, and all the tests achieved 100% sensitivity (153/153; 95%CI, 97.63-100) after 13 days from symptoms onset. NP-Total Ig was the earliest to attain maximal sensitivity among the other antibodies tested. Our newly developed serological testing exhibited 100% sensitivity and specificity after 13 days from symptoms onset. Hence, it could be used as a reliable method for accurate detection of COVID-19 patients and to evaluate seroprevalence and possibly for surrogate assessment of herd immunity.
Identifiants
pubmed: 33519790
doi: 10.3389/fmicb.2020.628281
pmc: PMC7843449
doi:
Types de publication
Journal Article
Langues
eng
Pagination
628281Informations de copyright
Copyright © 2021 Kubo, Ohtake, Miyakawa, Jeremiah, Yamaoka, Murohashi, Hagiwara, Mihara, Goto, Yamazaki, Ogura, Kaneko, Yamanaka and Ryo.
Déclaration de conflit d'intérêts
At the time of conducting the sudy, NO is a current employee of Tosoh Corporation and YY is a current employee of Kanto Chemical Co., Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32381641
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Adv Virus Res. 2006;66:193-292
pubmed: 16877062
Emerg Microbes Infect. 2020 Dec;9(1):940-948
pubmed: 32357808
Auto Immun Highlights. 2017 Dec;8(1):9
pubmed: 28647912
Nat Rev Immunol. 2020 Oct;20(10):583-584
pubmed: 32908300
Nat Commun. 2020 Aug 27;11(1):4303
pubmed: 32855401
Nat Commun. 2020 Jun 1;11(1):2806
pubmed: 32483236
Clin Infect Dis. 2021 Apr 8;72(7):1291-1292
pubmed: 32445559
Pathog Glob Health. 2020 Mar;114(2):64-67
pubmed: 32048560
Emerg Microbes Infect. 2020 Dec;9(1):382-385
pubmed: 32065055
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
J Infect Dis. 2020 Jun 29;222(2):206-213
pubmed: 32427334
Clin Transl Immunology. 2020 May 06;9(5):e01136
pubmed: 32382418
SLAS Technol. 2017 Oct;22(5):518-528
pubmed: 28095179
N Engl J Med. 2020 Oct 29;383(18):1724-1734
pubmed: 32871063
Clin Infect Dis. 2021 Jan 27;72(2):301-308
pubmed: 33501951
Viruses. 2014 Aug 07;6(8):2991-3018
pubmed: 25105276
Indian J Pediatr. 2020 Apr;87(4):281-286
pubmed: 32166607
Cureus. 2020 Jun 1;12(6):e8399
pubmed: 32499988
Clin Infect Dis. 2020 Jul 28;71(15):778-785
pubmed: 32198501
Immunity. 2020 Nov 17;53(5):925-933.e4
pubmed: 33129373
Cell Mol Immunol. 2020 Jul;17(7):773-775
pubmed: 32467617
Nat Protoc. 2007;2(6):1528-35
pubmed: 17571060
Elife. 2020 Sep 07;9:
pubmed: 32894217